Clinical Trials
Several clinical trials evaluate the diagnostic and prognostic utility of mebrofenin-based imaging across hepatic conditions such as liver dysfunction, regeneration, hepatocellular carcinoma, fibrosis, cirrhosis, and non-alcoholic steatohepatitis. Encompassing Phase 1 and observational designs, these studies are sponsored by academic centers including the McGill University Health Centre, Vilnius University, and the University of North Carolina at Chapel Hill. Spanning completed, actively recruiting, terminated, and withdrawn statuses, these protocols quantify hepatocyte function and hepatobiliary clearance to optimize risk stratification and patient management.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05280990 | WITHDRAWN | Liver Failure as A Complication of Care; 30-day Mortality |
Boris Gala Lopez |
2023-01-15 | |
| NCT06126419 | Recruiting | Liver Dysfunction|Liver Metastasis Colon Cancer|Liver Regeneration |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2023-11-08 | Not Applicable |
| NCT02235233 | COMPLETED | Non-alcoholic Steatohepatitis |
University of North Carolina, Chapel Hill |
2015-04 | PHASE1 |
| NCT00767468 | Terminated | Liver Cancer |
UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI) |
2008-10 | Phase 1 |
(data from https://clinicaltrials.gov, updated on 2024-02-07)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).